Non-oncotic effects of albumin as a carrier of sphingosine-1-phosphate (S1P) for the restoration of endothelial cell barriers and immune cell function in sepsis

Non-oncotic effects of albumin as a carrier of sphingosine-1-phosphate (S1P) for the restoration of endothelial cell barriers and immune cell function in sepsis - AlbuS1P-Studie

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027834

Enrollment

159

Registered

2022-02-21

Start date

2022-02-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis Hypoalbuminemia E88 A41

Interventions

Group 1: Blood drawn day 1,2,3 after albumin replacement patients with normal albumin levels and healthy controls (1-time) Group 2: Controls receive no albumin but have low levels <2g/L albumin Group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: ICU patients with Hypalbuminemia ICU patients with normal Albumin (3-5g/dL) Healthy controls

Exclusion criteria

Exclusion criteria: Missing consent <18 Years Moribund

Design outcomes

Primary

Measure	Time frame
Endothelial cell function (ECIS Assay) before and after application with albumin Immune cell migration (Migration Assay) before and after application with albumin	—

Secondary

Measure	Time frame
Clinical course	—

Countries

Germany

Contacts

Public ContactMartin Winkler

Universitätsmedizin Göttingen

martin.winkler@med.uni-goettingen.de0551-39-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026